MTNB$1.17-9.69%
Matinas BioPharma Holdings, Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: NYSE
Mkt Cap:$1.14M
Float & O/S:
Inst Own:
DilutionScan read 37 of Matinas BioPharma Holdings, Inc.'s SEC filings and found 7 warrant series, 2 convertibles, 1 ATM program, 3 shelf registrations and 2 completed offerings on file for MTNB. The latest dilution event on file is an offering on Jul 10, 2026. Analysis updated Oct 16, 2026.
Signal8 Summary
MTNB
Pending reverse merger and negative runway
Snapshot
Matinas is a distressed micro-cap with zero revenue and an exhausted cash runway after burning $7.0M in FY 2025 against a $4.0M cash balance. The company recently agreed to sell its primary drug assets and merge with GH Power, a move that would leave current shareholders with only about 9% of the combined clean energy entity.
What's Happening Right Now
- : Matinas agreed to merge with GH Power, where current shareholders would own about 9% of the new clean energy company, and sold its main drug assets to Azurity Pharmaceuticals for up to $21.5 million.
- : The NYSE American notified the company it is not in compliance with listing standards because its stockholders' equity is too low, though the exchange granted a cure period through October 2027.
